This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
REMATCH was a randomized, parallel, unmasked phase 3 treatment trial evaluating a left ventricular assist device against optimal medical therapy. The registry reports enrollment of 129 participants across two arms and identifies survival rate in the LVAD group at 2 years as the primary endpoint.
| Feature | REMATCH |
|---|---|
| Acronym | REMATCH |
| Phase | Phase 3 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 129 |
| Number of arms | 2 |
| Lead sponsor | Columbia University |
| Start date | 1997-10 |
| Primary completion date | 1999-03 |
| ClinicalTrials.gov | NCT00000607 |
2. Clinical Question
The registry describes REMATCH as a randomized phase 3 treatment study in cardiovascular and heart diseases, including heart failure and congestive heart failure. Its primary endpoint is survival rate in the LVAD group over a 2-year time frame.
Population
The registry lists cardiovascular diseases, heart diseases, heart failure, and heart failure, congestive as the study conditions.
Intervention
Left ventricular assist device, listed in the registry as a device intervention.
Comparator
Optimal medical therapy, also listed in the registry as a device intervention.
Primary question
The registered primary question is centered on survival rate in the LVAD group at 2 years.
3. Trial Design
Left ventricular assist device
- Intervention type: device
- Evaluated as one of the two randomized treatment strategies
Optimal medical therapy
- Intervention type: device as listed in the registry
- Serves as the comparator treatment strategy
The parallel randomized structure is statistically important because the primary comparison is between outcomes observed after assignment to the two treatment strategies. Randomization provides the framework for attributing differences in outcome to treatment assignment, subject to the usual assumptions and limitations of randomized trials.
4. Trial Timeline
Study start
The registry lists October 1997 as the study start date.
Primary completion
The registry lists March 1999 as the primary completion date.
The interval between the listed start and primary completion dates establishes the registered period of the trial, while the primary endpoint itself has a 2-year time frame. The registry does not provide additional endpoint results in its posted statistical analyses.
5. Primary Endpoint
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Survival rate in LVAD group | Survival rate in LVAD group | 2 years |
The endpoint is expressed as a survival rate rather than as a hazard ratio, median survival, or a time-to-event model in the registry's primary-endpoint entry. That distinction matters statistically: a survival rate at a fixed time point is an absolute proportion, whereas a hazard ratio describes a relative rate of the event over follow-up.
6. Statistical Methodology
Why survival is a time-to-event problem
Survival outcomes differ from ordinary binary outcomes because the timing of an event matters and because some participants may not experience the event during the observation period. Standard survival-analysis methods are designed to use both the observed event times and information from participants who remain event-free through their available follow-up.
Kaplan-Meier estimation
For a survival endpoint evaluated over time, a common nonparametric approach is the Kaplan-Meier estimator. It estimates the probability of remaining event-free at successive event times while accounting for right-censored observations.
Here, di is the number of events at time ti, and ni is the number of participants at risk immediately before that time.
The Kaplan-Meier estimate at a specified time, such as 2 years, is an estimate of the probability of surviving to that time under the observed follow-up and censoring framework.
Comparison of randomized groups
When survival is compared between randomized treatment groups, the log-rank test is a standard hypothesis-testing method, while a Cox proportional-hazards model can provide a hazard ratio and confidence interval. These approaches answer somewhat different questions from a single fixed-time survival rate.
Fixed-time survival rate
A 2-year survival rate is an absolute measure. If the estimated survival probability at 2 years were represented by S(2), then the quantity describes the estimated proportion surviving through that time point.
The quantity represents the probability that the event time T exceeds 2 years under the analysis population and censoring assumptions.
Confidence intervals
A confidence interval around a survival estimate quantifies statistical uncertainty in the estimated population survival probability. It should not be interpreted as a range containing the individual survival time of every participant.
Hypothesis testing
If the scientific question is whether survival differs between the randomized groups, a formal analysis would normally specify a null hypothesis concerning the treatment comparison and a corresponding test statistic. The registry's primary endpoint entry alone does not specify a particular test, effect estimate, or confidence interval.
7. Planned Analysis
The registered primary endpoint is survival rate in the LVAD group with a 2-year time frame. For a survival endpoint of this type, a standard analysis would estimate survival over time and report the survival probability at the prespecified time point, while appropriately accounting for censoring.
Primary estimand
The principal quantity is the survival probability at 2 years for participants assigned to the LVAD strategy.
Time-to-event framework
Survival analysis is appropriate because the endpoint concerns whether and when the event occurs during follow-up.
Typical estimation
Kaplan-Meier estimation is commonly used to estimate survival probabilities across follow-up and at fixed time points.
Typical comparison
For a randomized two-group survival comparison, a log-rank test and Cox model are common inferential tools when their assumptions and prespecified analysis plan support their use.
This distinction is important for interpreting the registry. An endpoint registration tells the reader what outcome was designated for measurement and over what time frame; it does not, by itself, establish the observed magnitude of an effect or its statistical significance.
8. How to Interpret a 2-Year Survival Endpoint
A fixed-time survival endpoint can be especially intuitive because it answers a direct clinical question: what proportion of the analyzed population is estimated to remain alive at a specified time?
A survival rate at 2 years is an absolute probability. It describes survival to a particular time point rather than comparing the instantaneous event rates between two groups.
A survival probability and a hazard ratio are not interchangeable. A hazard ratio summarizes a relative event rate under a fitted time-to-event model, whereas a fixed-time survival rate describes survival probability at one specified time.
Participants whose final observed follow-up occurs before the 2-year assessment may be censored rather than automatically classified as having experienced the event. The validity of a survival estimate therefore depends on the assumptions underlying the censoring process.
A point estimate alone does not describe its statistical precision. A complete inferential presentation would ordinarily accompany the estimated survival probability with an appropriate confidence interval.
9. Statistical Methods Explained
Why is Kaplan-Meier estimation relevant to REMATCH?
The registered primary endpoint is survival over a 2-year time frame. Kaplan-Meier estimation is designed for outcomes where both event timing and censoring are relevant, making it a standard framework for estimating survival probabilities over follow-up.
What does a 2-year survival rate mean?
It is the estimated probability of surviving through 2 years. Unlike a median survival time, it does not identify the time at which 50% of participants have experienced the event. Unlike a hazard ratio, it does not directly express a relative event rate between treatment groups.
Why is censoring important?
If a participant has not experienced the event when follow-up ends, the participant may contribute survival information up to the last observation without being counted as an event at that time. Kaplan-Meier methods incorporate this information rather than treating every incomplete follow-up as an event.
What would a log-rank test answer?
A log-rank test is commonly used to compare survival distributions between randomized groups. Its null hypothesis concerns the equality of survival experience between groups over follow-up, rather than a particular fixed-time survival percentage alone.
What would a Cox model add?
A Cox proportional-hazards model can summarize a randomized-group comparison with a hazard ratio and confidence interval. The interpretation depends on the proportional-hazards assumption, which concerns the relative hazards remaining reasonably stable over time under the model.
Why distinguish the endpoint from the analysis?
An endpoint specifies what is measured and when. The statistical analysis specifies how that measurement is estimated and compared, including treatment of censoring, the analysis population, hypothesis testing, and uncertainty. These are related but distinct parts of a clinical-trial statistical plan.
10. Analysis Population and Randomization
The registry identifies the allocation as randomized and the design model as parallel. These features define the basic statistical structure of the treatment comparison.
| Design feature | Registry description | Statistical significance |
|---|---|---|
| Allocation | Randomized | Creates the basis for comparing outcomes according to assigned treatment. |
| Design model | Parallel | Each randomized participant belongs to one treatment arm for the parallel comparison. |
| Masking | None | Treatment assignment was not masked according to the registry. |
| Primary purpose | Treatment | The study was designed to evaluate treatment strategies. |
Randomization is particularly important for causal interpretation because treatment assignment is determined by the randomized design rather than by an investigator's decision based on observed participant characteristics. The absence of masking, however, remains a design feature that can matter for outcomes or assessments susceptible to knowledge of treatment assignment.
11. Intervention Comparison
| Arm | Intervention | Registry classification |
|---|---|---|
| LVAD arm | Left ventricular assist device | Device |
| Comparator arm | Optimal medical therapy | Device |
The registry identifies the two interventions as the left ventricular assist device and optimal medical therapy. The comparison therefore concerns two distinct treatment strategies within a randomized parallel design.
From a statistical perspective, the important distinction is between assignment and outcome. Randomization determines which treatment strategy a participant is assigned to; the survival endpoint subsequently measures the participant's outcome over the specified follow-up period.
12. What the Registry Reports — and What It Does Not
The ClinicalTrials.gov record establishes a concise statistical framework for REMATCH: a phase 3 randomized parallel treatment study, 129 participants, two arms, and a primary endpoint defined as survival rate in the LVAD group at 2 years.
| Item | Registry status |
|---|---|
| Enrollment | 129 |
| Number of arms | 2 |
| Primary endpoint | Survival rate in LVAD group |
| Primary endpoint time frame | 2 years |
| Posted statistical analyses | None |
| Primary endpoint estimate | Not reported in the ClinicalTrials.gov statistical-analysis entry |
| Confidence interval | Not reported in the ClinicalTrials.gov statistical-analysis entry |
| p-value | Not reported in the ClinicalTrials.gov statistical-analysis entry |
This distinction prevents the registry's design information from being mistaken for an observed treatment effect. A registered endpoint identifies the intended outcome measure; statistical results require an accompanying reported analysis.
13. Limitations and Interpretation Issues
- No posted statistical analyses: the ClinicalTrials.gov record does not provide a reported estimate, confidence interval, p-value, or hazard ratio for the registered primary endpoint.
- Limited endpoint detail: the registry defines the primary endpoint as survival rate in the LVAD group at 2 years but does not provide additional endpoint-analysis specifications in the posted statistical-analysis information.
- Unmasked design: the registry identifies masking as none. Knowledge of treatment assignment can be relevant to aspects of trial conduct or assessment, although the effect depends on the particular outcome and measurement process.
- Censoring: survival analysis requires appropriate handling of incomplete follow-up. Without detailed follow-up information, the censoring pattern and its implications cannot be characterized from the registry entry alone.
- No reported event counts: the registry information does not provide the number of survival events by treatment arm.
- No reported confidence interval: without an interval estimate, the statistical precision of the primary endpoint cannot be assessed from the registry endpoint entry.
- No reported comparative effect: the registered survival-rate endpoint does not itself provide a comparison between the LVAD and optimal-medical-therapy arms.
- No subgroup information: the registry information does not report subgroup-specific survival estimates or treatment-effect estimates.
14. Why This Trial Matters Statistically
REMATCH provides a useful teaching example because its registered primary endpoint is a fixed-time survival measure embedded within a randomized phase 3 parallel design. That combination illustrates the distinction between study design, endpoint definition, and statistical estimation.
| Statistical concept | How it appears in REMATCH |
|---|---|
| Randomization | The registry identifies the allocation as randomized. |
| Parallel design | The registry identifies the design model as parallel with two arms. |
| Time-to-event analysis | The primary endpoint is survival rate over a 2-year time frame. |
| Fixed-time estimation | The endpoint specifies survival at a particular time horizon rather than a median or hazard ratio. |
| Kaplan-Meier methodology | A standard framework for estimating survival probabilities while accounting for censoring. |
| Log-rank testing | A standard method for comparing survival distributions between randomized groups. |
| Cox regression | A standard model for estimating relative hazards when its assumptions are appropriate. |
| Confidence intervals | Needed to describe uncertainty around an estimated survival probability or comparative effect. |
| Unmasked treatment | The registry identifies masking as none, which is relevant to interpretation of the trial design. |
15. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The trial has a randomized, parallel phase 3 design and a registered survival-rate endpoint evaluated at 2 years. A complete statistical interpretation would require the reported survival estimate and its associated uncertainty and comparative analysis.
Clinical interpretation
The registry identifies the comparison as a left ventricular assist device versus optimal medical therapy in a treatment study involving cardiovascular and heart diseases, including congestive heart failure. The clinical meaning of the observed comparison depends on the actual reported outcomes.
Keeping these levels separate is important. Statistical analysis describes how evidence is quantified and how much uncertainty surrounds it. Clinical interpretation considers what those quantified outcomes mean in the context of the disease and treatment strategies.
16. Reading Survival Curves Correctly
Although the registry identifies survival rate at 2 years as the primary endpoint, a survival analysis is generally richer than a single number. A survival curve displays the estimated probability of remaining alive across time and can reveal whether treatment-group differences emerge early, persist, or change during follow-up.
A fixed-time survival rate answers how much of the population is estimated to survive to a specified time. Median survival identifies the time at which estimated survival reaches 50%, when that point is observed. A hazard ratio summarizes relative event rates under a proportional-hazards model.
These measures can be complementary rather than interchangeable. Reporting a fixed-time survival rate can make the absolute status at an important time point transparent, while a survival curve provides the temporal context and a hazard ratio summarizes a relative treatment comparison.
17. The Role of the 2-Year Time Frame
The 2-year time frame is part of the registered definition of the primary endpoint. A fixed horizon has a practical statistical advantage: it defines a single time point at which the survival probability is evaluated.
Interpretability
A fixed-time estimate can be communicated directly as the estimated proportion surviving to the specified time point.
Precision
The precision of the estimate depends on the amount and quality of follow-up information available by that time.
Censoring
Participants without an observed event by the end of available follow-up contribute information through their censoring time.
Comparison
If treatment groups are compared, the analysis must distinguish an absolute survival probability from a relative measure such as a hazard ratio.
18. A Statistical Reading of Randomized Treatment Effects
The randomized design establishes the treatment comparison, but the design alone does not determine the magnitude of an observed effect. That magnitude must come from the outcome analysis.
For a survival endpoint, several layers of evidence can be considered:
- Absolute survival: the estimated probability of survival at the prespecified time point.
- Difference in survival: the absolute difference between treatment-group survival probabilities at a specified time.
- Relative survival effect: a ratio-based measure such as a hazard ratio, when a suitable model is prespecified and appropriate.
- Uncertainty: confidence intervals around the estimated treatment effect.
- Hypothesis testing: a prespecified statistical test and its associated p-value, when reported.
Each layer answers a different question. A statistically precise estimate can still require clinical context, while a clinically important-looking difference can be statistically uncertain when the available information is limited.
19. Important Distinctions for Survival Analysis
| Quantity | Question answered | Key caution |
|---|---|---|
| Survival rate at 2 years | What proportion is estimated to survive to 2 years? | Depends on follow-up and censoring assumptions. |
| Survival curve | How does estimated survival change over time? | Requires sufficient event and censoring information. |
| Median survival | When does estimated survival reach 50%? | May not be estimable if the survival curve does not reach 50%. |
| Hazard ratio | How do instantaneous event rates compare under a fitted model? | Interpretation depends on model assumptions, including proportional hazards for the standard Cox interpretation. |
| P-value | How incompatible are the observed data with a specified null hypothesis under the chosen test? | It does not measure effect size or clinical importance. |
| Confidence interval | How precisely is the statistical quantity estimated? | It does not describe the range of individual patient outcomes. |
20. Why a P-Value Would Not Be Enough
For a randomized survival comparison, a p-value can be useful for evaluating a prespecified null hypothesis, but it does not describe the magnitude of the treatment effect.
The effect size answers how different the treatment groups appear to be. For survival, this might be an absolute difference in 2-year survival or a relative measure such as a hazard ratio.
The confidence interval answers how uncertain the estimated effect is under the statistical model and sampling framework.
The p-value answers a different question: how compatible the observed data are with a particular null hypothesis under the specified statistical test.
A rigorous interpretation therefore considers the effect estimate, confidence interval, and statistical test together rather than treating a p-value as a substitute for the estimated treatment effect.
21. No Subgroup or Safety Analysis in the Registry Entry
The ClinicalTrials.gov information presented for REMATCH does not provide subgroup-specific survival results, serious adverse-event counts by treatment arm, or other safety estimates. Consequently, those quantities are not part of the statistical interpretation of this registry record.
This is a useful reminder that trial design registration and statistical results are separate components of clinical-trial reporting. A registry may establish the design and endpoint framework without supplying the numerical outcome analysis needed for a full efficacy or safety comparison.
22. Limitations of Fixed-Time Survival Analysis
A 2-year survival rate is clinically interpretable, but it compresses the entire survival experience into one time point. Two treatment groups could have the same survival rate at 2 years while having different survival trajectories before that point.
For this reason, a complete survival analysis would ordinarily examine the survival curve as well as the prespecified fixed-time estimate. The curve can show when treatment-group separation occurs and whether the relative difference appears stable over follow-up.
23. Why This Trial Is a Useful Statistical Teaching Case
REMATCH illustrates a foundational clinical-trial workflow: define the population and treatment comparison, randomize participants, specify a clinically meaningful time-to-event endpoint, and then choose an analysis that respects the timing of events and incomplete follow-up.
Design first
The registry identifies randomization, parallel allocation, two arms, and a treatment purpose before any statistical result is considered.
Endpoint second
The primary endpoint is explicitly defined as survival rate in the LVAD group with a 2-year time frame.
Analysis third
Survival methods such as Kaplan-Meier estimation and, when appropriate, log-rank and Cox methods provide standard ways to analyze this type of endpoint.
Interpretation last
The clinical meaning of the treatment comparison depends on the observed effect size, uncertainty, and trial context rather than on the trial design alone.
24. Sources
- ClinicalTrials.gov: NCT00000607 — REMATCH.
Continue through the Clinical Biostats clinical-trial library
Explore additional clinical-trial statistical analyses and educational material on study design, endpoints, survival analysis, and clinical-trial methodology.
25. Record Summary
REMATCH is registered as a randomized phase 3 treatment trial with a parallel design, no masking, two arms, and enrollment of 129 participants. The interventions are a left ventricular assist device and optimal medical therapy, and the registered primary endpoint is survival rate in the LVAD group over 2 years.
Statistically, the trial is a useful example of how a fixed-time survival endpoint fits within a randomized clinical-trial framework. The appropriate analytical perspective distinguishes the 2-year survival probability from comparative measures such as a hazard ratio, while recognizing the importance of censoring, confidence intervals, and prespecified hypothesis testing.